IPP Bureau
NITI Aayog organises workshop on ‘Strengthening Mental Health Services and Care in India’
By IPP Bureau - January 12, 2024
The workshop was conducted as a part of the NITI–State workshop series
Aarti Pharmalabs sets up R&D Centre in Navi Mumbai
By IPP Bureau - January 11, 2024
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Krishna Venkatesh elevated to Global Head - Quality and Pharmacovigilance of Dr. Reddy’s Laboratories
By IPP Bureau - January 11, 2024
He is also inducted as a member of the management council and senior management personnel of the company
Lupin launches Varenicline Tablets in US
By IPP Bureau - January 11, 2024
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
BioAsia 2024 to focus on data and AI for life sciences
By IPP Bureau - January 11, 2024
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Shanghai Argo announces multi-program RNAi licenses with Novartis
By IPP Bureau - January 11, 2024
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Unichem receives ANDA approval for Doxazosin Tablets
By IPP Bureau - January 11, 2024
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
Deloitte expands Quartz AI suite with Atlas AI for drug discovery
By IPP Bureau - January 11, 2024
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
SyntheticGestalt collaborates with Enamine to create AI-based model to facilitate drug discovery
By IPP Bureau - January 11, 2024
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
By IPP Bureau - January 10, 2024
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
USFDA accepts sBLA of TIVDAK for priority review for patients with metastatic cervical cancer
By IPP Bureau - January 10, 2024
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Kokilaben Dhirubhai Ambani Hospital introduces revolutionary HIFU Technology for prostate cancer treatment
By IPP Bureau - January 10, 2024
HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
Hikal invests Rs. 500 crore into fine chemicals plant at Panoli
By IPP Bureau - January 10, 2024
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
Tata 1mg and Vitonnix UK get into an exclusive partnership in India
By IPP Bureau - January 10, 2024
Launch innovative vitamin sublingual sprays
Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio
By IPP Bureau - January 10, 2024
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
